NEO212 Study Shows Increased Cytotoxicity for Temozolomide Resistant Glioma Tumor Cells

Initial Study Shows NEO 212 Temozolomide Conjugate As A Novel Drug For Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas.

Authors: Hee-Yeon Cho¹, Weijun Wang¹, Niyati Jhaveri², David Jungpa Lee², Natasha Sharma⁴, Louois Dubeau², Axel H. Schönthal³, Florance M. Hofman^1,2, and Thomas C. Chen^1,2

A study using NeOnc Technologies’ NEO 212 conjugate of Temozolomide with its highly purified Peryllyl Alcohol shows an increased ability to be able to target and kill glioblastoma tumor cells that have become resistant to Temzolomide without causing harm to surrounding healthy cell. 

The study was conducted to determine a better and more sustainable therapy course for patients with Glioblastoma brain cancer, one of the most deadly forms of cancer we deal with today. Temozolomide is one of the standards of care for chemotherapeutic treatment of patients with this form of cancer. However, in most instances, patients develop a resistance to the drug as therapy continues, thereby experiencing diminishing positive effects on its ability to slow or stop cancer cell growth. 

This study showed that by exposing these temozolomide-resistant cancer cells in-vivo to NEO 212, the efficacy of the temozolomide was restored and induced cancer-cell death without causing any perceived deleterious effects to normal cells. 

Departments of ¹Neurosurgery, ²Pathology, and ³ Molecular Microbiology & Immunology, Keck School of Medicine; ⁴ Departments of Pharamceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA.